North America Medical Isotope Market Size, Share & Trends Analysis Report By Type, By End User (Hospitals, Diagnostic Centers, and Research Institutes), By Application (Diagonostic, and Nuclear Therapy), By Country and Growth Forecast, 2023 - 2030

The North America Medical Isotope Market would witness market growth of 7.8% CAGR during the forecast period (2023-2030).

The US market dominated the North America Medical Isotope Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,322.1 million by 2030. The Canada market is experiencing a CAGR of 10.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 9.3% during (2023 - 2030).



The medical isotope market is crucial in modern healthcare, providing essential tools for diagnostic imaging, treatments, and medical research. Medical isotopes, or radiopharmaceuticals, are radioactive substances used in nuclear medicine procedures to diagnose and treat various medical conditions. Medical isotopes play a vital role in diagnostic imaging, allowing healthcare professionals to visualize and assess physiological processes within the body. From identifying tumors, assessing organ function, detecting abnormalities, and monitoring treatment response, medical isotopes provide valuable diagnostic information that helps guide patient care.

Furthermore, the development of clinical guidelines and protocols for using medical isotopes has standardized practices and increased confidence among healthcare providers. Evidence-based recommendations help guide the appropriate selection, administration, and interpretation of isotopic imaging studies and therapeutic interventions. Increased awareness among healthcare professionals and patients about the benefits and applications of medical isotopes has contributed to their adoption. Educational initiatives, professional development programs, and patient advocacy efforts have helped disseminate information about the role of medical isotopes in healthcare.

The expansion of the healthcare sector in Canada creates growth opportunities for companies involved in the production, distribution, and utilization of medical isotopes. According to data released by the Canadian government in 2023, provinces and territories will receive an additional $46.2 billion in financing as part of a $196.1 billion ten-year government investment to enhance health care services for all Canadians. Hence, the growing healthcare sector and pharmaceutical industry in the region is propelling the market’s growth.

Based on Type, the market is segmented into Radioisotopes, and Stable Isotopes. Based on End User, the market is segmented into Hospitals, Diagnostic Centers, and Research Institutes. Based on Application, the market is segmented into Diagnostic, and Nuclear Therapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Mallinckrodt PLC
• Bayer AG
• GE HealthCare Technologies, Inc.
• Canadian Nuclear Laboratories (Atomic Energy Of Canada Limited)
• ITM Isotope Technologies Munich SE
• Siemens Healthineers AG
• Eczacibasi-Monrol
• NorthStar Medical Radioisotopes, LLC
• Nordion Inc. (Sotera Health LLC)
• Iba SA

Market Report Segmentation

By Type

• Radioisotopes
• Stable Isotopes

By End User

• Hospitals
• Diagnostic Centers
• Research Institutes

By Application

• Diagnostic
• Nuclear Therapy

By Country

• US
• Canada
• Mexico
• Rest of North America